Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ganoderma acid y in preparation of medicine for treating or preventing enterovirus 71 infection

A technology of enterovirus and ganoderma acid, applied in the field of medicine, can solve the problems that the prevention and treatment of enterovirus 71 has not been mentioned and applied, and the antiviral effect of coxsackie virus has not been reported, so as to achieve safety and effectiveness Toxicity and side effects, improvement of treatment quality and administration compliance, and improvement of survival rate

Inactive Publication Date: 2011-12-14
WUHAN UNIV
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although ganoderma acid has been mentioned in the fields of anti-liver damage and anti-HIV virus, the antiviral effect on Coxsackie virus has not been reported before, and the effect on enteroviruses that are more popular and highly pathogenic now The preventive and therapeutic effects of type 71 (EV71) have not yet been mentioned and applied.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ganoderma acid y in preparation of medicine for treating or preventing enterovirus 71 infection
  • Application of ganoderma acid y in preparation of medicine for treating or preventing enterovirus 71 infection
  • Application of ganoderma acid y in preparation of medicine for treating or preventing enterovirus 71 infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Drug toxicity test (MTT method)

[0050] After 24-48 hours of culture, when the RD cells are almost covered with a single layer, the culture medium is discarded, digested with trypsin, and transferred to a 96-well sterile cell culture plate, 100 μl per well. Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. The drug was diluted step by step with cell culture medium. After diluting, add different concentrations of drugs into the cell culture wells where the supernatant was discarded, 100 μl per well, repeat 3 wells for each concentration, and set up cell control wells (no drugs, only culture solution), and then each well Add 100 μl of cell culture medium, place in a 37°C, 5% CO2 incubator, and cultivate for 48 hours, add 20ul of MTT solution (5mg / ml prepared in PBS, pH=7.4) to each well. Continue to incubate for 4h, terminate the culture, be careful Aspirate and discard the culture supernatant in the well. Fo...

Embodiment 2

[0054] Determination of half infectious dose (TCID50) of EV71 on cells

[0055] Transfer the RD cells cultured into a single layer to a 96-well cell culture plate, and place them in a cell culture incubator for 18-24 hours. The virus liquid was serially diluted 10 times (10-1...10-8) with the maintenance solution. Discard the culture medium in each well of RD cultured into a monolayer, wash each well with PBS 3 times, add 100 μl of virus solution of different concentrations to each well, absorb at 37°C for 1.5 h, discard the virus dilution solution, and add 100 μl to each well Maintenance solution, 10 repetitions for each concentration, set normal cell control wells. The cytopathic changes (CPE) in each well were observed daily for 3 consecutive days, and the CPE conditions were recorded. The titer of the virus was then calculated by the following formula.

[0056] PD / [log(dilution bov 50%)-log(dilution below 50%)]=[(%next above50%)-50%] / [(%next above 50%)-(%next below 50%)...

Embodiment 3

[0059] Experiments on the antiviral effect of ganoderma acid Y on EV71:

[0060] 1) The preventive effect of ganoderma acid Y on EV71 virus infection:

[0061]After 24-48 hours of culture, when the RD cells are almost covered with a single layer, the culture medium is discarded, digested with trypsin, and transferred to a 96-well sterile cell culture plate, 100 μl per well. Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. The drug was diluted step by step with cell culture medium. After dilution, add different concentrations of drugs into the cell culture wells where the supernatant was discarded, 100 μl per well, repeat 3 wells for each concentration, and set up cell control wells (no virus, no drug, only culture solution) and Virus control wells (without adding drugs, adding virus, and adding culture medium). After drug incubation for 1 hour, discard the supernatant, wash three times with PBS, add virus diluted...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of ganoderic acid Y to the preparation of a medicament for treating or preventing enterovirus 71 infection. The invention proves that the ganoderic acid Y has a good in-vitro antivirus effect in an enterovirus 71 infection cell test. Meanwhile, the ganoderic acid Y has a certain killing effect on enterovirus 71, can be used for preventing the infection of the enterovirus 71, and has a good treatment effect on cells infected by the enterovirus 71 and a good inhibiting effect on virus replication; and the acting effect of the ganoderic acid Y is more remarkable than ribavirin serving as a positive control medicament. Moreover, the ganoderic acid Y has a good inhibiting effect on inflammatory reactions caused by the enterovirus 71, and the prospect of the development of the medicament into an anti-enterovirus 71 medicament is disclosed.

Description

technical field [0001] The invention relates to the technical field of medicine, and more specifically relates to the application of ganoderma acid Y in the preparation of medicines for treating or preventing enterovirus 71 (EV71) infection. Background technique [0002] Enterovirus 71 (human enterovirus 71, EV71) is a member of the Picornaviridae Enterovirus genus and was first isolated in 1969 from fecal samples of infants with central nervous system diseases in California. Usually EV71 infection will cause hand, foot and mouth disease, which is mild and mostly self-limiting, which is difficult to distinguish from hand, foot and mouth disease caused by Coxsackie A16. In addition, EV71 can also cause aseptic meningitis, brainstem encephalitis, acute flaccid paralysis, acute cardiopulmonary dysfunction and other serious neurological diseases, and even death. In recent years, EV71 has repeatedly caused disease outbreaks or epidemics in the world. For example, large-scale EV7...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/575A61P29/00A61P31/14
Inventor 吴建国张文婧陶君彦邬开朗金晶朱应
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com